EarLens pulls in $36M for infrared hearing aid
March 3, 2014 by Brad Perriello
EarLens said it raised some $36 million in an equity round for the hearing aid technology it’s developing that uses infrared rather than sound waves.
The Redwood City, Calif.-based company, which is led by a former Abbott Vascular honcho, said 22 unnamed investors had participated in the round as of Feb. 24. EarLens is hoping to raise a total of $38.8 million, according to a regulatory filing. Read more
Cheetah Medical closes $9M funding round
March 3, 2014 by Brad Perriello
Cheetah Medical said it added another $9 million to its coffers in a funding round led by Fletcher Spaght Ventures.
The Newton, Mass.-based medical device company makes a non-invasive hemodynamic monitoring system, said Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures also participated in the round. Read more
Surgical lighting company Invuity lands $36M Series E round
March 4, 2014 by Arezu Sarvestani
San Francisco surgical lighting company Invuity Inc. secured $36 million in a Series E funding round, planning on using the new cash to "accelerate commercial initiatives."
Invuity develops hand-held lighting systems that aim to improve visibility and access during minimally invasive surgeries. The company’s proprietary Eigr lighting technology combines lighting with tissue retractors so that the illumination remains inside of incisions. Read more
Benvenue Medical closes $3.5M funding round
March 3, 2014 by Arezu Sarvestani
Spinal devices maker Benvenue Medical closed a $3.5 million funding round with the help of 9 unnamed investors, according a regulatory filing.
The Santa Clara, Calif.-based company raised the funds through sales of debt, rights and securities or rights to acquire securities. Benvenue provided few other details on the funding round. Read more
NxThera closes $20M Series C round
March 4, 2014 by Brad Perriello
NxThera said it closed a $20 million Series C round that topped its initial $18 million target.
Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia. Read more